Rice Shauna M, Ferree Sarah D, Mesinkovska Natasha Atanaskova, Kourosh Arianne Shadi
Massachusetts General Hospital, Department of Dermatology, Boston, MA, United States.
Cambridge Health Alliance, Cambridge, MA, United States.
Int J Womens Dermatol. 2021 Mar;7(2):209-212. doi: 10.1016/j.ijwd.2021.01.007. Epub 2021 Jan 12.
As COVID-19 vaccinations begin, dermatologists must be aware of the cutaneous adverse events reported in the clinical trials, including injection site and hypersensitivity reactions, and emerging evidence of dermal filler injection reactions after vaccination. The filler reaction may represent the development of a delayed-type hypersensitivity in the setting of another immunologic trigger (i.e., the vaccine). After conducting a literature review of similar reactions, their pathophysiology, and management, we present a set of timely clinical considerations for counseling, prevention, and management of possible cutaneous sequelae of the COVID-19 vaccine. We encourage documentation of vaccine-related reactions to aid the safety data collection in the Vaccine Adverse Event Reporting System and the American Academy of Dermatology COVID-19 Registry.
随着新冠病毒疫苗接种工作的展开,皮肤科医生必须了解临床试验中报告的皮肤不良事件,包括注射部位反应和过敏反应,以及接种疫苗后出现的真皮填充剂注射反应的新证据。填充剂反应可能表现为在另一种免疫触发因素(即疫苗)作用下迟发型超敏反应的发生。在对类似反应、其病理生理学及处理方法进行文献综述后,我们提出了一系列及时的临床考量,用于咨询、预防和处理新冠病毒疫苗可能导致的皮肤后遗症。我们鼓励记录与疫苗相关的反应,以协助疫苗不良事件报告系统和美国皮肤病学会新冠病毒登记处收集安全数据。